Phase III trial enrolling up to 30,000 adults aged 18 years or over to assess safety, efficacy and immunogenicity of AZD 1222 for the prevention of COVID-19.-AstraZeneca
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest